Open AccessAngiotensin‐Converting Enzyme I/D Polymorphism in Patients With Malignant Hypertension
Author(s) -
Espinel Eugenia,
Tovar Jose Luis,
Borrellas Javier,
Piera Luis,
Jardi Rosendo,
Frias Francisco Rodriguez,
Armadans Luis,
Bachs Ana Gonzalez
Publication year - 2005
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2005.03879.x
Subject(s) - medicine , polymorphism (computer science) , angiotensin converting enzyme , cardiology , genetics , blood pressure , genotype , gene , biology
The angiotensin‐converting enzyme (ACE) gene has been implicated in the manifestation of the phenotype of malignant hypertension (MH). In 1990 the ACE gene polymorphism characterized by the insertion or deletion of a 287‐base pair fragment in the 17q23 chromosome was identified. The DD genotype is associated with increased tissue and circulating ACE levels and elevated angiotensin II. ACE polymorphism was studied in 48 patients with MH, 25 patients with non‐MH, and a control group of 78 normotensive individuals by real‐time polymerase chain reaction using the LightCycler system (Roche Diagnostics Corporation, Indianapolis, IN). The DD genotype was found statistically more frequently in MH patients than controls (p=0.028; odds ratio, 2.5; confidence interval, 1.1–5.5). Presence of the DD genotype of the ACE gene is more frequent in MH patients than in controls, indicating that this genotype could be a significant risk factor and a predictor for the development of MH.